Publications
Publishing the Frontiers of Immuno-Oncology
Spotlight Publication
Botensilimab (Fc-enhanced anti-CTLA-4), Balstilimab (PD-1 inhibitor)
Emerging survival plateaus with botensilimab and balstilimab: Pan tumor data from a large phase 1b trial of advanced solid tumors
Oct 17, 2025
,
Gordon et al.
ESMO
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Balstilimab (PD-1 inhibitor)
Botensilimab (Fc-enhanced anti-CTLA-4)
Neoadjuvant botensilimab (BOT) plus balstilimab (BAL) in resectable mismatch repair proficient and deficient colorectal cancer
ESMO
European Society for Medical Oncology, Gastrointestinal (ESMO-GI)
June 28, 2024
,
Kasi, et. al.
Balstilimab (PD-1 inhibitor)
Botensilimab (Fc-enhanced anti-CTLA-4)
Botensilimab (BOT) plus balstilimab (BAL) in microsatellite stable metastatic colorectal cancer: Assessing efficacy in non-liver metastatic sites
ASCO
American Society of Clinical Oncology (ASCO)
June 1, 2024
,
Fakih, et al.
AGEN1777
BMS-986442 (AGEN1777), a novel TIGIT/CD96 bispecific antibody, demonstrates superior monotherapy and combination activity versus conventional anti-TIGIT antibodies in preclinical models
AACR
American Association of Cancer Research (AACR)
April 8, 2024
,
Chand, et al.
No items found.
Botensilimab (Fc-enhanced anti-CTLA-4)
Balstilimab (PD-1 inhibitor)
Neoadjuvant botensilimab plus balstilimab (BOT/BAL) in resectable mismatch repair proficient and deficient colorectal cancer: NEST-1 clinical trial.
ASCO
American Society for Clinical Oncology, Gastrointestinal (ASCO-GI)
January 20, 2024
,
Kasi, et. al.